

Special Issue

Emerging Technologies in Liquid Biopsy of Cancers

Message from the Guest Editor

This Special Issue explores cutting-edge technological advances in the field, with an emphasis on novel methodologies such as high-sensitivity detection platforms (single-cell analysis, microfluidics, CRISPR-based assays), multi-omics integration (fragmentomics, epigenomics, proteomics), and AI-driven bioinformatics pipelines; emerging biomarkers, with the discovery and validation of novel signatures (cfDNA fragmentation patterns, methylation profiles, metabolite panels) for early cancer detection, the monitoring of minimal residual disease, and the prediction of therapy resistance; and clinical translation, with developments addressing challenges such as low-abundance target isolation, the standardization of pre-analytical protocols, and longitudinal monitoring to accelerate clinical adoption. We welcome original research, reviews, and perspectives on in silico biomarker discovery, point-of-care devices, nanotechnology applications, and multi-modal liquid biopsy frameworks. Submissions should highlight technological novelty, analytical/clinical validation, and translational potential across solid and hematologic malignancies

Guest Editor

Dr. Lingdi Yin

Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/245866

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).